Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aadi Bioscience Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AADI
Nasdaq
2834
https://aadibio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aadi Bioscience Inc
Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 25th, 2023 9:30 pm
Aadi Bioscience to Participate in Upcoming Investor Events
- May 23rd, 2023 12:00 pm
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
- May 10th, 2023 12:00 pm
Aadi Bioscience to Report First Quarter 2023 Results and Operational Update
- May 3rd, 2023 12:00 pm
Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apr 26th, 2023 8:05 pm
Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting
- Apr 14th, 2023 5:00 pm
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023
- Apr 6th, 2023 8:30 pm
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
- Mar 28th, 2023 12:00 pm
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
- Mar 27th, 2023 12:00 pm
Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer
- Mar 26th, 2023 6:00 pm
Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update
- Mar 15th, 2023 12:00 pm
Aadi Bioscience Announces Leadership Transition
- Mar 3rd, 2023 1:00 pm
Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference
- Feb 22nd, 2023 1:00 pm
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
- Nov 17th, 2022 1:00 pm
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
- Nov 9th, 2022 1:00 pm
Aadi Bioscience Announces Planned Leadership Transition
- Nov 8th, 2022 9:00 pm
Aadi Bioscience to Present at Upcoming Investor Conferences
- Nov 3rd, 2022 12:00 pm
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium
- Oct 27th, 2022 12:00 pm
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
- Oct 12th, 2022 12:00 pm
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
- Sep 22nd, 2022 8:01 pm
Scroll